ClinicalTrials.gg
CompletedNCT01120132Updated Mar 9, 2012

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

A Phase 2 interventional study of CsA high dose and CsA low dose in Allergic Conjunctivitis, sponsored by Fovea Pharmaceuticals SA. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-09.

Sponsored by Fovea Pharmaceuticals SA · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
716
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.

Enrollment
3rd of 90
716 · median 94
Started
2010
with 7 others
Phase 2
25 of 95
4 open now
Registered
30th of 95
by date

Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 3rd largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2010, is one of 25 in phase 2, and was the 30th registered.

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.

Browse Conjunctivitis, Allergic studies →

Open to participants now

6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Conjunctivitis, Allergic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of the administration of cyclosporine and prednisolone acetate compared to placebo in the treatment of allergic conjunctivitis.

03

Conditions studied

  • Allergic Conjunctivitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • history of ocular allergies and a positive skin test reaction to perennial allergens within the past 24 months and a history of chronic eye irritation
  • visual acuity score ≥ 0.60 (EDTS)
  • negative urine pregnancy test for female patients, and use of adequate throughout the study period.

Exclusion criteria

Exclusion Criteria:

  • active ocular infection; preauricular lymphadenopathy or ocular condition that could affect study; glaucoma or abnormal intraocular pressure; ocular surgery within past 3 months; history of asthma, pregnancy or nursing
  • or known allergies to the study drug(s)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
716 participants (actual)

Study arms

  • Experimental
    Cyclosporine low dose , Prednisolone Acetate

    Administration of a solution of Cyclosporine (low dose) and a suspension of Prednisolone Acetate

    Drug: CsA low dose · Drug: PA

  • Experimental
    Cyclosporine high dose, Prednisolone Acetate

    Administration of a solution of Cyclosporine (high dose) and a suspension of Prednisolone Acetate

    Drug: CsA high dose · Drug: PA

  • Experimental
    Cyclosporine high dose

    Administration of a solution of Cyclosporine (high dose) and Placebo

    Drug: CsA high dose · Drug: Placebo

  • Experimental
    Cyclosporine low dose

    Administration of a solution of Cyclosporine (low dose) and Placebo

    Drug: CsA low dose · Drug: Placebo

  • Active comparator
    Prednisolone Acetate

    Administration of a suspension of Prednisolone Acetate and Placebo

    Drug: PA

  • Placebo comparator
    Placebo

    Administration of Placebo

    Drug: Placebo

Interventions

  • DrugCsA high dose

    Solution of Cyclosporine (high dose) administered during 28 days

  • DrugCsA low dose

    Solution of Cyclosporine (low dose) administered during 28 days

  • DrugPA

    Suspension of Prednisolone Acetate administered during 28 days

  • DrugPlacebo

    Placebo solution administered during 28 days

06

What researchers measure

Primary outcomes

  1. Diary assessment of signs and symptoms of ocular allergy

    Patient-reported ocular itching and redness

    Time frame: During the 28 days of treatment

Secondary outcomes

  1. Diary and office assessments of various ocular and nasal allergy signs and symptoms

    Patient-reported ocular itching and redness, lid swelling, tearing and nasal itching Investigator assessments of ocular redness and chemosis

    Time frame: During 28 days of treatment

  2. Safety

    Ocular tolerance and adverse events

    Time frame: During the 28 days of treatment

07

Study locations

1 site
  • ORA
    Andover, Massachusetts 01810, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2010
First posted
May 10, 2010
Start
May 2010
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Last update
Mar 9, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01120132
Lead sponsor
Fovea Pharmaceuticals SA
Responsible party
Sponsor
First posted
May 10, 2010
Start date
May 2010
Primary completion
Aug 2010
Completion
Aug 2010
Last update
Mar 9, 2012

Study contacts

Marie-Louise Jacques, MD MBA
study chair · Fovea Pharmaceuticals SA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion